Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Leukemia

Free Subscription 19.12.2011 1 Biochem Pharmacol 14 Blood 3 Br J Cancer 8 Br J Haematol 1 Cancer Chemother Pharmacol 1 Cell 3 Eur J Haematol 1 Exp Hematol 2 Int J Hematol 2 J Biol Chem 2 J Clin Oncol 1 J Immunol 6 Leuk Lymphoma 19 Leuk Res 12 Leukemia 4 N Engl J Med 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Biochem Pharmacol

1. PARK B , Sung B, Yadav VR, Chaturvedi MM, et al
   Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
   Biochem Pharmacol. 2011;82:1134-44.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Blood

2. MILOJKOVIC D , Apperley JF, Gerrad G, Ibrahim AR, et al
   Responses to second line tyrosine kinase inhibitors are durable: an intention to treat analysis in chronic myeloid leukemia patients.
   Blood. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. HWANG KK , Chen X, Kozink DM, Gustilo M, et al
   Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by co-culture with macrophage feeder cells.
   Blood. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. KANTARJIAN HM , Shah NP, Cortes JE, Baccarani M, et al
   Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
   Blood. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. MCDERMOTT SP , Eppert K, Notta F, Isaac M, et al
   A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside.
   Blood. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. VAWDA A , Davis J, Vercauteren S
   Leukemic transformation of anaplastic large-cell lymphoma.
   Blood. 2011;118:3763.
   PubMed     Text format     Related articles   
   
   
   
7. PIERI L , Spolverini A, Scappini B, Occhini U, et al
   Concomitant occurrence of BCR-ABL and JAK2V617F mutation.
   Blood. 2011;118:3445-6.
   PubMed     Text format     Related articles   
   
   
   
8. HARRISON CJ
   Key pathways as therapeutic targets.
   Blood. 2011;118:2935-6.
   PubMed     Text format     Related articles   
   
   
   
9. NAHAR R , Ramezani-Rad P, Mossner M, Duy C, et al
   Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.
   Blood. 2011;118:4174-8.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. MAGENAU J , Tobai H, Pawarode A, Braun T, et al
    Clofarabine and busulfan conditioning facilitates engraftment and provides significant anti-tumor activity in non-remission hematologic malignancies.
    Blood. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. ROBB RJ , Kreijveld E, Kuns RD, Wilson YA, et al
    Type I-IFNs control GVHD and GVL responses after transplantation.
    Blood. 2011;118:3399-409.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. BALUSU R , Fiskus W, Rao R, Chong DG, et al
    Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
    Blood. 2011;118:3096-106.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. KARUBE K , Nakagawa M, Tsuzuki S, Takeuchi I, et al
    Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses.
    Blood. 2011;118:3195-204.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. ZHANG Y , Stehling-Sun S, Lezon-Geyda K, Juneja SC, et al
    PR domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cells function.
    Blood. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. KUCHENBAUER F , Mah SM, Heuser M, McPherson A, et al
    Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.
    Blood. 2011;118:3350-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Br J Cancer

16. BASTA NO , James PW, Gomez-Pozo B, Craft AW, et al
    Survival from childhood cancer in northern England, 1968-2005.
    Br J Cancer. 2011;105:1402-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. REID A , Glass DC, Bailey HD, Milne E, et al
    Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to extremely low frequency electromagnetic fields.
    Br J Cancer. 2011;105:1409-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. ROYLE JA , Baade PD, Joske D, Girschik J, et al
    Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study.
    Br J Cancer. 2011;105:1076-81.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Br J Haematol

19. PORTELL CA , Sekeres MA, Rogers HJ, Tiu RV, et al
    De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
    Br J Haematol. 2011 Dec 8. doi: 10.1111/j.1365-2141.2011.08972.
    PubMed     Text format     Related articles   
    
    
    
20. TADMOR T , Bejar J, Attias D, Polliack A, et al
    Richter syndrome in chronic lymphocytic leukaemia manifesting only as tumorous hepatomegaly.
    Br J Haematol. 2011;155:135.
    PubMed     Text format     Related articles   
    
    
    
21. ANDERSEN MK , Autio K, Barbany G, Borgstrom G, et al
    Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols.
    Br J Haematol. 2011;155:235-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. NORDIGARDEN A , Zetterblad J, Trinks C, Green H, et al
    Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
    Br J Haematol. 2011;155:198-208.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. BECKER PS , Kantarjian HM, Appelbaum FR, Petersdorf SH, et al
    Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
    Br J Haematol. 2011;155:182-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. RIPPERGER T , Tauscher M, Praulich I, Pabst B, et al
    Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia.
    Br J Haematol. 2011;155:209-17.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. FRANDSEN TL , Abrahamsson J, Lausen B, Vettenranta K, et al
    Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
    Br J Haematol. 2011;155:244-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. FORRESTER AM , Grabher C, McBride ER, Boyd ER, et al
    NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis.
    Br J Haematol. 2011;155:167-81.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Cancer Chemother Pharmacol

27. WEISS J , Haefeli WE
    Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Cancer Chemother Pharmacol. 2011;68:1093-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Cell

28. GREBIEN F , Hantschel O, Wojcik J, Kaupe I, et al
    Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
    Cell. 2011;147:306-19.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Eur J Haematol

29. CHOW KU , Kim SZ, von Neuhoff N, Schlegelberger B, et al
    Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
    Eur J Haematol. 2011;87:426-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. KRISTENSEN T , Moller MB, Friis L, Bergmann OJ, et al
    NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.
    Eur J Haematol. 2011;87:400-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. ROUG AS , Nyvold CG, Juhl-Christensen C, Christensen M, et al
    A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
    Eur J Haematol. 2011;87:461-3.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Exp Hematol

32. WILSON NK , Tijssen MR, Gottgens B
    Deciphering transcriptional control mechanisms in hematopoiesis:the impact of high-throughput sequencing technologies.
    Exp Hematol. 2011;39:961-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Int J Hematol

33. YAGI T , Ishikawa J, Aono N, Yamashita Y, et al
    Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma.
    Int J Hematol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. TSUKAMOTO S , Takeuchi M, Kawajiri C, Tanaka S, et al
    Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
    Int J Hematol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Biol Chem

35. ZHAO XY , Zhao KW, Jiang Y, Zhao M, et al
    Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute myeloid leukemic cells.
    J Biol Chem. 2011;286:36808-19.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. ALVIRA D , Naughton R, Bhatt L, Tedesco S, et al
    Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.
    J Biol Chem. 2011;286:32313-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Clin Oncol

37. GOLDIN LR , Kristinsson SY, Liang XS, Derolf AR, et al
    Familial Aggregation of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. PARSONS HM , Harlan LC, Seibel NL, Stevens JL, et al
    Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?
    J Clin Oncol. 2011;29:4045-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Immunol

39. ZELINSKYY G , Myers L, Dietze KK, Gibbert K, et al
    Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication.
    J Immunol. 2011;187:3730-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Leuk Lymphoma

40. AOKI J , Ohashi K, Kobayashi T, Kakihana K, et al
    Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles   
    
    
    
41. ELSE M , Cocks K, Crofts S, Wade R, et al
    Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. JONES JA , Kraut EH, Deam D, Byrd JC, et al
    Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles   
    
    
    
43. DE BRAEKELEER E , Douet-Guilbert N, Meyer C, van Deventer FM, et al
    MLL-ELL fusion gene in 2 infants with acute monoblastic leukemia and myeloid sarcoma.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles   
    
    
    
44. FOSTER MC , Amin C, Voorhees PM, van Deventer HW, et al
    A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Patients with Refractory or Relapsed Acute Myeloid Leukemia.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. TIU R , Kalaycio M
    Targeted Therapy for Patients with Chronic Myeloid Leukemia: Clinical Trial Experience and Challenges in Intertrial Comparisons.
    Leuk Lymphoma. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Leuk Res

46. TRIFILIO SM , Rademaker AW, Newman D, Coyle K, et al
    Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
    Leuk Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. SANCHEZ-GONZALEZ B , Penalver FJ, Medina A, Guillen H, et al
    Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Leuk Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. KLIMEK VM , Dolezal EK, Smith L, Soff G, et al
    Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia.
    Leuk Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. SUCH E , Cervera J, Ibanez M, Gomez-Segui I, et al
    Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).
    Leuk Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
50. PASTORCZAK A , Gorniak P, Sherborne A, Hosking F, et al
    Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.
    Leuk Res. 2011;35:1534-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. HARROD R
    Inhibiting HDACs in a preclinical model of HTLV-1-induced adult T-cell lymphoma.
    Leuk Res. 2011;35:1436-7.
    PubMed     Text format     Related articles   
    
    
    
52. CRAIG BM , Rollison DE, List AF, Cogle CR, et al
    Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
    Leuk Res. 2011;35:1453-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. BRECCIA M , Loglisci G, Cannella L, Serrao A, et al
    Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.
    Leuk Res. 2011;35:e215-6.
    PubMed     Text format     Related articles   
    
    
    
54. SONTANI Y , Chapman G, Papathanasiou P, Dunwoodie S, et al
    Cooperation between somatic Ikaros and Notch1 mutations at the inception of T-ALL.
    Leuk Res. 2011;35:1512-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. ROSE C , Fournier M, Nibourel O, Herbaux C, et al
    Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.
    Leuk Res. 2011;35:e203-5.
    PubMed     Text format     Related articles   
    
    
    
56. ZIMMERMAN B , Sargeant A, Landes K, Fernandez SA, et al
    Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
    Leuk Res. 2011;35:1491-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. KRISHNADAS DK , Stamer MM, Dunham K, Bao L, et al
    Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Leuk Res. 2011;35:1520-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
58. ISHIBASHI M , Tamura H, Ogata K
    Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment.
    Leuk Res. 2011;35:1449-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. KOIVULA I , Juutilainen A
    Procalcitonin is a useful marker of infection in neutropenia.
    Leuk Res. 2011;35:1288-9.
    PubMed     Text format     Related articles   
    
    
    
60. HOLROYD A , Cross NC, Macdonald DH
    The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
    Leuk Res. 2011;35:1279-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. STACCHINI A
    Flow cytometric detection of BCR-ABL in cerebrospinal fluid.
    Leuk Res. 2011;35:1286-7.
    PubMed     Text format     Related articles   
    
    
    
62. RAUW J , Wells RA, Chesney A, Reis M, et al
    Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.
    Leuk Res. 2011;35:1335-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. WIKTOR AE , Van Dyke DL, Hodnefield JM, Eckel-Passow J, et al
    The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years.
    Leuk Res. 2011;35:1297-300.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. D'ALESSIO F , Mirabelli P, Mariotti E, Raia M, et al
    Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease.
    Leuk Res. 2011;35:1290-3.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Leukemia

65. SPECTOR MS , Iossifov I, Kritharis A, He C, et al
    Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A.
    Leukemia. 2011 Dec 16. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles   
    
    
    
66. LODER S , Fakler M, Schoeneberger H, Cristofanon S, et al
    RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis.
    Leukemia. 2011 Dec 16. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. NORDLUND J , Kiialainen A, Karlberg O, Berglund EC, et al
    Digital gene expression profiling of primary acute lymphoblastic leukemia cells.
    Leukemia. 2011 Dec 16. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. LUIS TC , Ichii M, Brugman MH, Kincade P, et al
    Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development.
    Leukemia. 2011 Dec 15. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. BELLONI E , Shing D, Tapinassi C, Viale A, et al
    In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels.
    Leukemia. 2011;25:1922.
    PubMed     Text format     Related articles   
    
    
    
70. TSUBOI A , Oka Y, Kyo T, Katayama Y, et al
    Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.
    Leukemia. 2011 Dec 13. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles   
    
    
    
71. LIU P , Xu B, Shen W, Zhu H, et al
    Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.
    Leukemia. 2011 Dec 13. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
72. GILES FJ , Kantarjian HM, le Coutre PD, Baccarani M, et al
    Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
    Leukemia. 2011 Dec 13. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. ISHIYAMA K , Takami A, Kanda Y, Nakao S, et al
    Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant.
    Leukemia. 2011 Dec 9. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles   
    
    
    
74. JANSSEN JJ , Deenik W, Smolders KG, van Kuijk BJ, et al
    Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
    Leukemia. 2011 Dec 9. doi: 10.1038/leu.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
75. KREUTZMAN A , Ladell K, Koechel C, Gostick E, et al
    Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
    Leukemia. 2011;25:1587-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
76. SULIS ML , Saftig P, Ferrando AA
    Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL.
    Leukemia. 2011;25:1564-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    N Engl J Med

77. WANG L , Lawrence MS, Wan Y, Stojanov P, et al
    SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia.
    N Engl J Med. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. KOCHENDERFER JN , Rosenberg SA
    Chimeric antigen receptor-modified T cells in CLL.
    N Engl J Med. 2011;365:1937-8.
    PubMed     Text format     Related articles   
    
    
    
79. YEH CC
    Chimeric antigen receptor-modified T cells in CLL.
    N Engl J Med. 2011;365:1937.
    PubMed     Text format     Related articles   
    
    
    
80. DI STASI A , Tey SK, Dotti G, Fujita Y, et al
    Inducible apoptosis as a safety switch for adoptive cell therapy.
    N Engl J Med. 2011;365:1673-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Proc Natl Acad Sci U S A

81. LOGAN AC , Gao H, Wang C, Sahaf B, et al
    High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Proc Natl Acad Sci U S A. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. MERTZ JA , Conery AR, Bryant BM, Sandy P, et al
    Targeting MYC dependence in cancer by inhibiting BET bromodomains.
    Proc Natl Acad Sci U S A. 2011;108:16669-74.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: